Protein Critical for Action of Thyroid Cancer Drug-- A. Agrawal, PhD
Thursday, February 12, 2009
THURSDAY, Feb. 12 (HealthDay News) -- A cellular protein is a critical mediator in the signaling pathway of a drug that inhibits the growth of thyroid cancer cells, according to a report published online Feb. 10 in Cancer Research.
Extending earlier results, Laura A. Marlow, from the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Fla., and colleagues investigated how the high affinity PPAR-gamma agonist RS5444 induced the cyclin dependent kinase inhibitor p21 and inhibited the growth of anaplastic thyroid carcinoma cells.
The investigators found that RhoB was a critical mediator of the actions of RS5444. The researchers report that RS5444 induced expression of RhoB, while blocking RhoB expression blocked the ability of RS5444 to induce p21 expression and block cell growth. Increasing the expression of RhoB led to increased expression of p21 and inhibition of cell proliferation, even in cells unable to respond to RS5444.
"Our results implicate RhoB as a novel intermediate in critical signaling pathways and as an additional target for therapeutic intervention in anaplastic thyroid carcinoma," Marlow and colleagues conclude.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.
September 01, 2014
November 25, 2015